<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40291">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02045823</url>
  </required_header>
  <id_info>
    <org_study_id>Maestro2000AP</org_study_id>
    <nct_id>NCT02045823</nct_id>
  </id_info>
  <brief_title>OCT Agreement and Precision Study</brief_title>
  <official_title>Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate clinical substantial equivalence of 3D OCT-1 Maestro as comparable to the
      commercially available iVue and NW-300.  Also, to demonstrate clinical substantial
      equivalence of 3D OCT-2000 Maestro as comparable to the commercially available NW-300.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Normal Eyes</condition>
  <condition>Eyes With Glaucoma</condition>
  <condition>Eyes With Retinal Disease</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Normal results from clinical exam and free of ocular pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retina</arm_group_label>
    <description>clinical exam with results consistent with retina pathology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that are Normal, or shows signs of Glaucoma, or Retinal Ocular Pathology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand  the written informed consent and willing  to Criteria
             participate as evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes (eyes without pathology)

          4. lOPs  21mmHg  bilaterally

          5. BCVA 20/40 or better  (each eye)

          6. Both eyes must be free of eye disease

        Exclusion Criteria for Normal Group

          1. Subjects unable to tolerate  ophthalmic  imaging

          2. Subject with ocular media not sufficiently  clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or  PSD &lt; 5%

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses&gt; 33% or false positives&gt;
             25%, or false negatives&gt; 25%

          5. Presence of any ocular pathology except for cataract

          6. Previous ocular surgery or laser treatment, other than uncomplicated refractive
             procedure or cataract surgery, performed within  six months prior to study scanning

          7. Narrow  angle

          8. History of leukemia, dementia  or multiple  sclerosis

          9. Concomitant  use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Glaucoma Group

          1. Subjects 18 years of age or older on the date of informed  consent

          2. Subjects able to understand the written informed consent and willing to participate
             as evidenced by signing the informed consent

          3. Subjects presenting at the site with glaucoma

          4. BCVA 20/40 or better  in the study eye

          5. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or  PSD &lt; 5% in the study eye

        Exclusion Criteria for Glaucoma Group

          1. Subjects unable to tolerate ophthalmic  imaging

          2. Subject with ocular media not sufficiently  clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined  as
             fixation losses&gt; 33% or false positives&gt; 25%, or false negatives &gt; 25% in the study
             eye

          4. Presence of any ocular pathology except glaucoma in the study eye

          5. Previous ocular surgery or laser treatment, other than uncomplicated refractive
             procedure  or cataract surgery, performed within six months prior to study scanning
             in the study eye

          6. History of leukemia, dementia  or multiple  sclerosis

          7. Concomitant  use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Retina Disease Group

          1. Subjects 18 years of age or older on the date of informed  consent

          2. Subjects able to understand the written informed consent and willing to participate
             as evidenced by signing the informed consent

          3. Subjects presenting at the site with retinal disease

          4. lOP&lt;= 21mmHg in the study eye

          5. BCVA 20/400 or better  in the study eye

          6. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to:  Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

        Exclusion Criteria for Retinal Disease Group

          1. Subjects unable to tolerate ophthalmic  imaging

          2. Subject with ocular media not sufficiently  clear to obtain acceptable OCT images

          3. Presence of glaucoma or any ocular pathology  other than a Retinal pathology (e.g.,
             cornea pathology) in the study eye

          4. Previous ocular surgery or laser treatment other than uncomplicated refractive
             procedure or cataract surgery, performed within  six months prior to study scanning
             in the study eye

          5. Narrow angle in the study eye

          6. History of leukemia, dementia  or multiple  sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Sinai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Sinai, PhD</last_name>
    <phone>760-476-3305</phone>
    <email>msinai@topcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York VA</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murray Fingeret, OD</last_name>
      <phone>718-298-8498</phone>
      <email>murray.fingeret@va.gov</email>
    </contact>
    <investigator>
      <last_name>Murray Fingeret, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
